US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

413.68

+18.254.62%

Number of Gainers:4

Number of Losers:2

Number of Flat:- -

PE:- -

High:418.89

Open:394.14

Low:387.79

Close:395.43

Loading ...

Beam Therapeutics (BEAM) Gets a Hold from Barclays

Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23

THOMSON REUTERS

Beam Therapeutics Reports 2024 Financial Results and Progress

Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027

THOMSON REUTERS

Beam Therapeutics Q4 Operating Expenses USD 130.104 Million

THOMSON REUTERS

Beam Therapeutics Q4 EPS USD -1.09 VS. Ibes Estimate USD -1.2

THOMSON REUTERS

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

bluebird bio Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4556/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":413.68384,"timestamp":1741381199999,"preClose":395.43274,"halted":0,"volume":13723847,"delay":0,"changeRate":0.046155,"change":18.251099,"pbRate":1.9827,"amount":163649532.723433,"amplitude":0.078654,"prevYearClose":376.62552,"fiveDayClose":396.1103,"twentyDayClose":388.3015,"turnoverRate":0.025125,"marketCap":7685371892,"floatMarketCap":7202041036,"peRate":-3.812751},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":418.8933,"amplitude":0.078654,"preClose":395.43274,"low":387.79083,"pbRate":"1.9827","latestPrice":413.68384,"volume":13723847,"delay":0,"open":394.13995,"prevYearClose":376.62552,"prevWeekClose":413.6838,"prevMonthClose":396.1103,"prevQuarterClose":376.6255,"fiveDayClose":396.1103,"twentyDayClose":388.3015,"sixtyDayClose":415.7698,"secType":"PLATE","market":"US","turnoverRate":0.025125,"peRate":-3.812751,"marketCap":7685371892,"floatMarketCap":7202041036,"timestamp":1741381199999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":4,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514887477","title":"Beam Therapeutics (BEAM) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887477?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:20","pubTimestamp":1740565218,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-hold-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-hold-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4556","BK4139","BK4585","BEAM","BK4535","BK4588"],"gpt_icon":0},{"id":"2514009390","title":"Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009390?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:01","pubTimestamp":1740553294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4505","BK4139","BK4585","BK4556","BK4588","BEAM"],"gpt_icon":0},{"id":"2514074303","title":"Beam Therapeutics Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074303?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:21","pubTimestamp":1740543708,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. ( ($BEAM) ) has released its Q4 earnings. Here is a breakdown of the information Beam Therapeutics, Inc. presented to its i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4097","LENZ","BK4505","LU2065732104.USD","BK4139","BK4585","BK4556","PRGS","BK4588","BEAM"],"gpt_icon":0},{"id":"2514809344","title":"Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809344?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLXBC8901:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BEAM","BK4505","BK4556","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2514098920","title":"Beam Therapeutics Q4 Operating Expenses USD 130.104 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098920?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLXBC8901:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","BK4535","BEAM","BK4139","BK4556","BK4588"],"gpt_icon":0},{"id":"2514098180","title":"Beam Therapeutics Q4 EPS USD -1.09 VS. Ibes Estimate USD -1.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098180?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLXBC8901:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4535","BK4505","BK4585","BK4139","BEAM","BK4588"],"gpt_icon":0},{"id":"2514093342","title":"Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093342","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093342?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031842/0/en/Beam-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Reiterates-Anticipated-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","BK4505","BEAM","BK4535","LENZ","SCD","BK4109","BK4588","LU2463526074.USD","ASH","BK4585"],"gpt_icon":0},{"id":"2513722401","title":"Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722401","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722401?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:15","pubTimestamp":1740406500,"startTime":"0","endTime":"0","summary":"Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform. Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability. SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc.  has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/illumina-transforms-multiomic-research-technologies-141500613.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illumina-transforms-multiomic-research-technologies-141500613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4556","LU1861559042.SGD","BK4534","BK4121","BK4139","BK4585","BK4535","CRSP","BK4588","LU1861558580.USD","ILMN"],"gpt_icon":0},{"id":"2513721098","title":"Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721098","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721098?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 24, 2025  -- Editas Medicine, Inc. , a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March:. TD Cowen 45th Annual Health Care Conference Format: Fireside ChatDate: Monday, March 3Time: 2:30 p.m. ETLocation: Boston, MA. Leerink Partners Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, March 10Time: 9:20 a.m. ETLocation: Miami, FL. Barclays 27th Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, March 11Time: 9:00 a.m. ETLocation: Miami, FL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/editas-medicine-announce-fourth-quarter-140000831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","LU1861559042.SGD","LU1861558580.USD","BK4588","CRSP","EDIT","BK4556"],"gpt_icon":0},{"id":"2513720437","title":"2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720437","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513720437?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics and Intellia Therapeutics are both unprofitable gene-editing companies.Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next year.Take CRISPR Therapeutics  and Intellia Therapeutics , two biotechs specializing in gene editing. The former's average price target, according to Yahoo!Finance, is $83.60; the latter earns a price target of $50.80 from analysts. That implies an upside of about 66% for CRISPR Therapeutics and 415% for Intellia Therapeutics.These two companies have significantly lagged the market over the past three years. Could they turn around and live up to Wall Street's expectations?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/24/2-beaten-down-stocks-to-buy-before-they-soar-by-66/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4556","LU1861559042.SGD","BK4139","CRSP","BK4585","BK4588","LU1861558580.USD","SCD"],"gpt_icon":1},{"id":"2513280397","title":"Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513280397","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513280397?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 24, 2025  -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:. TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ET. About Beam TherapeuticsBeam Therapeutics  is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-participate-upcoming-march-120000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4585","BK4535","BEAM","BK4139","BK4556","BK4588","LENZ"],"gpt_icon":0},{"id":"2513792033","title":"bluebird bio Inc : JP Morgan Raises to Neutral From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792033?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:23","pubTimestamp":1740374629,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","BK4556","BK4139","BLUE"],"gpt_icon":0},{"id":"2513800750","title":"Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513800750","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513800750?lang=en_us&edition=fundamental","pubTime":"2025-02-24 04:05","pubTimestamp":1740341119,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Beam Therapeutics Inc.  stands against the other best performing pharma stocks so far in 2025.On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump administration. Talking about the pharma’s agenda in Washington, where the big names of the pharma industry were set to meet with President Trump on February 20, Holz said that while it is tough to talk about the valuation of pharma companies, the significance of the meeting is to have a sort of collaborative effort between the industry and the government to see where they can move things over time. The stocks have exhibited either a little bit or a lot of worry over the RFK front, the United States Secretary of Health and Human Services. This was based on the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-beam-therapeutics-inc-beam-200519020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","NQmain","BK4139","SQQQ","BK4556","BK4585","QLD","QID","BK4535","MNQmain","TQQQ","BEAM","PSQ","USAW.SI","USJW.SI",".IXIC","TSYW.SI","NVIW.SI","BK4588"],"gpt_icon":1},{"id":"2513754757","title":"CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513754757","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513754757?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:34","pubTimestamp":1740335664,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CRISPR Therapeutics AG  stands against the other oversold pharma stocks to buy according to analysts.On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs. She believed the industry may not underperform this year, at least in the first half. However, there are still several questions surrounding the performance of obesity drugs, as major players in the domain have exhibited contrasting previous year performance.Angelica Peebles, CNBC’s Health and Pharma reporter, sat with Eli Lilly’s Chief Scientific Officer to talk about the weight loss sector. From the conversation, she reported that the domain poses opportunity for drugs that are easier to use, such as pills, and medicines that make peop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-most-183424796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","CRSP","NVIW.SI","BK4585","BK4210","LU1861559042.SGD","PSQ","BK4588","BK4139","BK4556","QID",".IXIC","TSYW.SI","NQmain","MNQmain","QLD","USJW.SI","TQQQ","SQQQ","AG","SCD","USAW.SI"],"gpt_icon":1}],"pageSize":16,"totalPage":3,"pageCount":3,"totalSize":46}]}}